The management of carcinoid tumours

QJM: An International Journal of Medicine

Volumn 91, Issue 12, 1998, Pages 795-798

  Halford, S ^a   Waxman, J ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; ALPHA INTERFERON; ANGIOPEPTIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FENCLONINE; FLUOROURACIL; KETANSERIN; METHYSERGIDE; OCTREOTIDE; ONDANSETRON; SEROTONIN; SOMATOSTATIN; STREPTOZOCIN;

APPENDIX; CARCINOID; CARCINOMA; CLINICAL TRIAL; DRUG HYPERSENSITIVITY; HUMAN; HYPOTENSION; LIVER METASTASIS; MENTAL DISEASE; META ANALYSIS; METASTASIS; NAUSEA; PRIORITY JOURNAL; PROGNOSIS; RECTUM; SEDATION; SHORT SURVEY; SIDE EFFECT; SUBCUTANEOUS DRUG ADMINISTRATION; TUMOR VOLUME; VERTIGO;

EID: 0032413578     PISSN: 00335622     EISSN: None     Source Type: Journal    
DOI: 10.1093/qjmed/91.12.795     Document Type: Short Survey

References (26)

1. Godwin DJ. Carcinoid Tumours; An Analysis of 2837 Cases. Cancer 1975; 36:560-9.
2. Makridis C, Öberg K, Juhlin C, et al. Surgical Treatment of Midgut Carcinoid Tumours. World J Surg 1990; 14:377-85.
3. Gerhardt CC, Van Heerikuizen. Functional Characteristics of Heterologously Expressed 5HT Receptors. Eur J Pharmacol 1997; 334:1-23.
4. Julius D, Livelli TJ, Jessel TM, Axel R. Ectopic Expression of the Serotonin lc Receptor and the Triggering of Malignant Transformation. Science 1989; 244:1057-62.
5. Launay J-M, Birraux G, Bondoux D, et al. Ras Involvement in Signal Transduction by the Serotonin 5HT2B Receptor. J Biol Chem 1996; 271:3141-7.
6. Satterlee WG, Serpick A, Bianchine JR. The Carcinoid Syndrome: Chronic Treatment with Para-Chlorophenylalanine. Ann Intern Med 1970; 72:919-21.
7. Coupe M, Levi S, Ellis M, et al. Therapy for Symptoms in the Carcinoid Syndrome. Q J Med 1989; 271:1021-36.
8. Gustafsen J, Lendorf A, Raskov H, Boesby S. Ketanserin Versus Placebo in Carcinoid Syndrome: A Clinical Controlled Trial. Scand J Gastroenterol 1986; 21:816-18.
9. Platt AJ, Heddle RM, Rake MO, Smedley N. Ondanseatron in Carcinoid Syndrome. Lancet 1992; 339:1416.
10. Kubuta A, Yamada Y, Kagimoto S, et al. Identification of Somatostatin Receptor Types and an Implication for the Efficiency of Somatostatin Analogue SMS 201-995 in Treatment of Neuroendocrine Tumours. J Clin Invest 1994; 93:1321-5.
11. Janmohamed S, Bloom SR. Carcinoid Tumours. Postgrad Med J 1997; 73:207-14.
12. Janson ET, Gobl A, Kalkner KM, Öberg K. A Comparison between the Efficacy of Somatostatin Receptor Scintigraphy and that of In Situ Hybridization for Somatostatin Receptor Subtype 2 Messenger RNA to Predict Therapeutic Outcome in Carcinoid Patients. Cancer Res 1996; 56: 2561-5.
13. Öberg K. Treatment of Neuroendocrine Tumours. Cancer Treatment Rev 1994; 20:331-55.
14. Ruszniewski X, et al. Treatment of the Carcinoid Syndrome with the Longacting Somatostatin Analogue Lanreotide: a Prospective Study in 39 Patients. Gut 1996; 39:279-83.
15. Davies PH, Stewart SE, Lancranjan I, Sheppard M, Stewart P. Long Term Therapy with Long-Acting Octrectide (Sandostatin-LAR) for the Management of Acromegaly. Clin Endocrinol 1998; 48:311-16.
16. Di Bartolomeo M, Bajetta E, Buzzoni R, et al. Clinical Efficacy of Octreotide in the Treatment of Metastatic Neuroendocrine Tumours, a Study by the Italian Trials in Medical Oncology Group. Cancer 1996; 77:402-8.
17. Moertel CG, Rubin J, Kvals LK. Therapy of Metastatic Carcinoid Tumour and the Malignant Carcinoid Syndrome with Recombinant Leukocyte A Interferon. J Clin Oncol 1998; 7:865-8.
18. Öberg K. Interferon-α Versus Somatostatin or the Combination of Both in Gastro-Enteropancreatic Tumours. Digestion 1996; 57(Suppl 1):81-3.
19. Taal BG, Hoefnagel CA, Valdes-Olmos RA, Boot H, Beijnen JH. Palliative Effect of Metaiodobenzylguanidine in Metastatic Carcinoid Tumours. J Clin Oncol 1996; 14:1829-38.
20. Krausz Y, Bar-Ziv J, de Jong RB, et al. Somatostatin-Receptor Scintigraphy in the Management of Gastroenteropancreatic Tumors. Am J Gastroenterol 1998; 93:66-70.
21. Moertel CG. Treatment of the Carcinoid Tumour and the Malignant Carcinoid Syndrome. J Clin Oncol 1983; 1:727.
22. Moertel CG, Hanky JA. Combination Chemotherapy Trials in Metastatic Carcinoid Tumour and the Malignant Carcinoid Syndrome. Cancer Clin Trials 1992: 327-34.
23. Engstrom PJ, Lavin PT, Folsch E. Streptozocin Plus Fluorouracil Versus Doxorubicin Therapy for Metastatic Carcinoid Tumours. J Clin Oncol 1984; 2:1255.
24. Bukowski R, Johnson K, Peterson R, et al. A Phase II Trial of Combination Chemotherapy in Patients with Metastaticv Carcinoid Tumours. Cancer 1987; 60:2891-5.
25. Moertel CG, Johnson CM, McKusick MA, et al. The Management of Patients with Advanced Carcinoid Tumors and Islet Cell Carcinomas. Ann Intern Med 1994; 120:302-9.
26. Diaco DS, Hajarizadeh H, Mueller C, Fletcher W, Pommier R, Woltering E. Treatment of Metastatic Carcinoid Tumors Using Multimodality Therapy of Octreotide Acetate, Intra-Arterial Chemotherapy, and Hepatic Chemoembolization. Am J Surg 1995; 169:523-8.